Latest Breaking News On - ஹீமாட்டாலஜி ஆண்டு சந்தித்தல் - Page 3 : vimarsana.com

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial and Operational Results

Posted on 344 Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today reports financial and operational results for the fourth quarter and year ended December 31, as well as guidance for anticipated 2021 milestones. “2021 is poised to be another exciting year for Rocket,” said Gaurav Shah, M.D., Chief Executive Officer of Rocket. “We anticipate clinical data from all five of our gene therapy programs, initiation of our first in-house AAV cGMP production from our new manufacturing facility, and continued strengthening of our organization, manufacturing capabilities and infrastructure. We look forward to continued validation of our gene therapy platforms with updated results from registrational studies in FA and LAD-I, longer term findings in Danon Disease and PKD, and clinical proof-of-concept for

United statesNew jerseyLos angelesCity ofUnited kingdomGaurav shahClaudine prowseCarlos garcia paradaKinnari patelUniversity of californiaCalifornia institute for regenerative medicineAmerican society of hematology annual meetingStrategy corporate developmentFanconi anemia research fundRocket pharmaceuticals incUniversity of colorado

AbbVie Reports Full-Year and Fourth-Quarter 2020 Financial Results

- Reports Full-Year Diluted EPS of $2.72 on a GAAP Basis; Adjusted Diluted EPS of $10.56 - Delivers Full-Year Net Revenues of $45.804 Billion on a GAAP Basis, an Increase of 37.7 Percent on a Reported Basis; Adjusted Net Revenues Were $45.784 Billion - Full-Year Global Net Revenues from the Immunology Portfolio Were $22.153 Billion, an Increase of 13.2 Percent on a Reported Basis, or 13.4 Percent on an Operational Basis; U.S. Humira Net Revenues Were $16.112 Billion, an Increase of 8.4 Percent; Internationally, Humira Net Revenues Were $3.720 Billion, a Decrease of 13.6 Percent on a Reported Basis, or 12.5 Percent on an Operational Basis, Due to Biosimilar Competition; Global Skyrizi Net Revenues Were $1.590 Billion; Global Rinvoq Net Revenues Were $731 Million

United statesAlphagan combiganLinzess constellaRicharda gonzalezLumigan ganfortOrilissa oriahnnJanssen biotech incAmerican society of hematology annual meetingBoehringer ingelheimEuropean unionOther women healthAbbvie incNational urban leagueDrug administrationWomen healthUnited negro college fund

Investegate |GlaxoSmithKline PLC Announcements | GlaxoSmithKline PLC: Final Results

GSK delivers FY 2020 reported sales of £34 billion, +1% AER, +3% CER and Adjusted EPS of 115.9p, -6% AER, -4% CER, in line with guidance; Total EPS 115.5p, +23% AER Highlights Strong sales performance from key growth drivers in HIV, Respiratory, Oncology and Consumer Healthcare offset disruption from COVID-19 to adult vaccinations · Pharmaceuticals £17 billion -3% AER, -1% CER; new and specialty products £9.7 billion +11% AER, +12% CER · · · New Biopharma product portfolio strengthened with 9 approvals in 2020 and Cabenuva in the US in January 2021 Effective cost control supports delivery of adjusted earnings per share in line with FY 2020 guidance · · · Significant progress on Biopharma pipeline with over 20 assets now in late-stage clinical trials

India generalUnited statesUnited kingdom generalUnited kingdomCity ofEmma walmsleySarah elton farrKathleen quinnJeff mclaughlinSimon steelSonya ghobrialJanssen rekambysTim foleyJames dodwellKristen neeseRelvar breo

Amgen Reports Fourth Quarter And Full Year 2020 Financial Results

Amgen Reports Fourth Quarter And Full Year 2020 Financial Results News provided by Share this article Share this article THOUSAND OAKS, Calif., Feb. 2, 2021 /PRNewswire/ Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year 2020 versus comparable periods in 2019. Key results include: For the fourth quarter, total revenues increased 7% to $6.6 billion in comparison to the fourth quarter of 2019, driven by higher volume growth, partially offset by lower net selling prices. Product sales increased 8% globally, driven by 13% volume growth across the portfolio, including Otezla ® (apremilast), MVASI ® (trastuzumab-anns), and Repatha ® (evolocumab), partially offset by declines in mature products that resulted from biosimilar and generic competition.

Puerto ricoUnited statesUnited kingdomNeulasta onproSensipar mimparaUs otezla trxTrish hawkinsRoberta bradwayNational institute of allergyMerck coResearch developmentAmerican academy of allergy asthmaSociety for immunotherapy of cancerBiomedical advanced researchEuropean commissionBeigene ltd

GT Biopharma : Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patie

GT Biopharma : Announces GTB-3550 TriKE(TM) Reduces Bone Marrow Blast Levels, Improves NK Cell Function and Proliferation, and No Toxicities Observed in AML and MDS Patie
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesAnthony cataldoErica warlickBeverly hillsExchange commissionAmerican society of hematologyNational cancer instituteAmerican society of hematology annual meetingUniversity of minnesotaGt biopharma incReduces bone marrow blast levelsResults presentedAmerican societyHematology annual meetingPrincipal investigatorOral session